OX40 Agonist Immunotherapy Expands Tumor Reactive CD8 T Cells With a Unique T Cell Receptor Repertoire and Synergizes With PDL-1 Blockade to Promote Tumor Regression

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-2-s3-o18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Intratumoral Tcf1+PD-1+cd8+ T Cells With Stem-Like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

Immunity
Infectious DiseasesAllergyImmunology
2019English

Soluble Γc Receptor Attenuates Anti-Tumor Responses of CD8+ T Cells in T Cell Immunotherapy

International Journal of Cancer
Cancer ResearchOncology
2018English

OX40- And CD27-Mediated Costimulation Synergizes With Anti–PD-L1 Blockade by Forcing Exhausted CD8+T Cells to Exit Quiescence

Journal of Immunology
AllergyImmunology
2014English

Measuring CD8+ T Cell Tumor Infiltration to Guide Immunotherapy Selection

Science-Business eXchange
2013English

CD4+T Cells Are Able to Promote Tumor Growth Through Inhibition of Tumor-Specific CD8+T-Cell Responses in Tumor-Bearing Hosts

Cancer Research
Cancer ResearchOncology
2005English

LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8+ T Cells

Journal of Immunology
AllergyImmunology
2019English

Failed Adoptive Immunotherapy With Tumor-Specific T Cells

Cancer Research
Cancer ResearchOncology
2004English

OX40-Enhanced Tumor Rejection and Effector T Cell Differentiation Decreases With Age

Journal of Immunology
AllergyImmunology
2009English

Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8 + T Cells

Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy